2024-05-02 18:27:57
The Federal Commission for the Protection against Health Risks (Cofepris) detected irregularities in a medicine against him cancer.
For this reason, he asked to suspend the application and distribution of “methotrexate injectable solution 500 mg”, distributed by Biosistemas y Seguridad Privada.
You might be interested in: Cofepris alert for counterfeit drugs for breast cancer and HIV
The agency identified discrepancies in the drug that treats cancer by slowing the growth of the cells that cause said disease, specifically with the HIMH23020 batch, which has an expiration date in August 2026.
In a statement, they request that the acquisition of medicines be only through authorized distributors validated by the company that owns the health registry, who must have a health license and operating notice issued by the agency.
You might be interested in: Cofepris recognizes Corte for labeling
In addition, the population is invited to report any adverse reaction or discomfort associated with the use of this product.
It was reported that monitoring of this treatment will be maintained.
EAM
Related
2024-05-02 18:27:57